ATE173617T1 - Transdermales matrixsystem auf eva basis zur verabreichung eines östrogens und/oder gestagens - Google Patents

Transdermales matrixsystem auf eva basis zur verabreichung eines östrogens und/oder gestagens

Info

Publication number
ATE173617T1
ATE173617T1 AT95400573T AT95400573T ATE173617T1 AT E173617 T1 ATE173617 T1 AT E173617T1 AT 95400573 T AT95400573 T AT 95400573T AT 95400573 T AT95400573 T AT 95400573T AT E173617 T1 ATE173617 T1 AT E173617T1
Authority
AT
Austria
Prior art keywords
pts
eva
progestagen
estrogen
administration
Prior art date
Application number
AT95400573T
Other languages
English (en)
Inventor
Eric Teillaud
Antoine Sawaya
Marie-Christine Math
Original Assignee
Lhd Lab Hygiene Dietetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lhd Lab Hygiene Dietetique filed Critical Lhd Lab Hygiene Dietetique
Application granted granted Critical
Publication of ATE173617T1 publication Critical patent/ATE173617T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT95400573T 1994-03-28 1995-03-15 Transdermales matrixsystem auf eva basis zur verabreichung eines östrogens und/oder gestagens ATE173617T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403598A FR2717688B1 (fr) 1994-03-28 1994-03-28 Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.

Publications (1)

Publication Number Publication Date
ATE173617T1 true ATE173617T1 (de) 1998-12-15

Family

ID=9461478

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95400573T ATE173617T1 (de) 1994-03-28 1995-03-15 Transdermales matrixsystem auf eva basis zur verabreichung eines östrogens und/oder gestagens

Country Status (23)

Country Link
US (1) US5605702A (de)
EP (1) EP0674900B1 (de)
JP (1) JPH07309762A (de)
KR (1) KR950031056A (de)
CN (1) CN1114587A (de)
AT (1) ATE173617T1 (de)
AU (1) AU684601B2 (de)
CA (1) CA2145579A1 (de)
CZ (1) CZ289211B6 (de)
DE (1) DE69506156T2 (de)
DK (1) DK0674900T3 (de)
ES (1) ES2127484T3 (de)
FI (1) FI951425A (de)
FR (1) FR2717688B1 (de)
GR (1) GR3029402T3 (de)
HU (1) HU219245B (de)
LV (1) LV10930B (de)
NO (1) NO308124B1 (de)
NZ (1) NZ270810A (de)
PL (1) PL179022B1 (de)
RU (1) RU2144818C1 (de)
SK (1) SK281234B6 (de)
ZA (1) ZA952468B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370220B1 (de) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen Applikation enthaltend Gestoden
AU692944B2 (en) * 1994-11-18 1998-06-18 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
FR2739032B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique
ATE302599T1 (de) 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
DE19700913C2 (de) * 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE10025970C2 (de) * 2000-05-25 2002-04-25 Lohmann Therapie Syst Lts Estrogenhaltiges Pflaster mit einem Wirkstoffreservoir auf der Basis von Ethylcellulose und einem Ethylen-Vinylacetat-Vinylpyrrolidon-Copolymer und seine Verwendung
DE10118282A1 (de) * 2001-04-12 2002-12-05 Lohmann Therapie Syst Lts Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
US7833545B2 (en) * 2003-04-29 2010-11-16 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
EP1684782B1 (de) 2003-10-03 2015-09-30 Thorn BioScience, LLC Verfahren zur synchronisierung der ovulation für zeitlich angepasstes brüten ohne hitzenachweis
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
CA2667678A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
CA2840407A1 (en) * 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CN102596215B (zh) 2009-04-23 2015-04-29 佩纳特克有限责任公司 用于同步授精时间的方法和组合物
SG193434A1 (en) 2011-03-16 2013-10-30 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2016508030A (ja) 2012-11-28 2016-03-17 ジェイビーエス ユナイテッド アニマル ヘルス セカンド エルエルシー 未経産ブタにおける授精の時期を同期化するための方法および組成物
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2970408B1 (de) 2013-03-12 2018-01-10 Amgen Inc. Hochwirksame und selektive inhibitoren von nav1.7
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
FR2612785A1 (fr) * 1987-03-25 1988-09-30 Lhd Lab Hygiene Dietetique Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5032402A (en) * 1988-10-27 1991-07-16 The University Of Kentucky Research Foundation 3-hydroxy-N-methylpyrrolidone and use as transdermal enhancer
IL92496A0 (en) * 1988-12-01 1990-08-31 Schering Corp Compositions for transdermal delivery of estradiol
EP0483370B1 (de) * 1990-05-17 1995-03-29 Hisamitsu Pharmaceutical Co., Inc. Estradiol enthaltende transdermale zubereitung

Also Published As

Publication number Publication date
GR3029402T3 (en) 1999-05-28
CN1114587A (zh) 1996-01-10
DE69506156T2 (de) 1999-07-22
LV10930A (lv) 1995-12-20
SK281234B6 (sk) 2001-01-18
DE69506156D1 (de) 1999-01-07
FR2717688A1 (fr) 1995-09-29
RU2144818C1 (ru) 2000-01-27
HUT75237A (en) 1997-05-28
FR2717688B1 (fr) 1996-07-05
EP0674900B1 (de) 1998-11-25
ES2127484T3 (es) 1999-04-16
CA2145579A1 (en) 1995-09-29
FI951425A0 (fi) 1995-03-24
JPH07309762A (ja) 1995-11-28
NO951125D0 (no) 1995-03-24
NO951125L (no) 1995-09-29
DK0674900T3 (da) 1999-06-23
PL179022B1 (en) 2000-07-31
NZ270810A (en) 1996-05-28
LV10930B (en) 1996-08-20
PL307889A1 (en) 1995-10-02
FI951425A (fi) 1995-09-29
SK39195A3 (en) 1995-10-11
HU219245B (en) 2001-03-28
KR950031056A (ko) 1995-12-18
NO308124B1 (no) 2000-07-31
CZ76895A3 (en) 1995-10-18
AU1497995A (en) 1995-10-05
AU684601B2 (en) 1997-12-18
CZ289211B6 (cs) 2001-12-12
ZA952468B (en) 1995-12-19
EP0674900A1 (de) 1995-10-04
US5605702A (en) 1997-02-25
HU9500881D0 (en) 1995-05-29

Similar Documents

Publication Publication Date Title
ATE173617T1 (de) Transdermales matrixsystem auf eva basis zur verabreichung eines östrogens und/oder gestagens
DE69506157T2 (de) Transdermales Matrixsystem auf Basis eines Styrol-Isopren-Styrol Copolymers zur Verabreichung eines Östrogens und/oder Gestagens
US6274165B1 (en) Transdermal, hormone-delivering therapeutic system
AU680050B2 (en) Transdermal therapeutic system containing octyl dodecanol ascrystallization inhibitor
NO980277L (no) Hormonplaster
RU99118582A (ru) Композиция для чрескожного введения стероидных лекарственных средств
EP0737477A4 (de) Transdermale pharmazeutische zubereitung
DE69924133D1 (de) Diethylentriaminpentaessigsäure enthaltende propofol-zusammensetzung
DE69205010D1 (en) Transdermales estradiol als therapeutisches system.
ATE69724T1 (de) Selbstklebende vorrichtung zur transdermalen verabreichung eines wirkstoffs.
ES8403323A1 (es) Instrumento canular para fluidos parenterales.
NO973471L (no) Transdermalt preparat
FR2635979B1 (fr) Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee
DE19613698A1 (de) Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee